Skip to content
stoqly

Rhythm Pharmaceuticals, Inc.

RYTM Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Revenue Total sales reported in the income statement.
$190M
45.8% vs prior year
Operating margin Operating income as a share of revenue.
−101.2%
102.8 pts
Net income Profit after all expenses, interest and tax.
−$197M
Free cash flow Cash from operations minus capital spending.
−$117M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$3.11 EPS (TTM)

What Rhythm Pharmaceuticals, Inc. does

No business description yet.

Legal name
RHYTHM PHARMACEUTICALS, INC.
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Feb 26, 2026
Accession · CIK
0001628280-26-012399
0001649904

Revenue and margins

Rhythm Pharmaceuticals, Inc. had $190M of revenue in fiscal 2025, up 45.8% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$117M in fiscal 2025, −61.5% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Rhythm Pharmaceuticals, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 6.5%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Rhythm Pharmaceuticals, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $295M$333M$276M$321M$389M
Debt incl. finance leases ——$106M$110M$108M
Debt / equity ——0.6x5.1x0.8x
Interest coverage —−34.4x−13.3x−12.9x−9.3x
Current ratio 7.1x8.9x5.6x3.2x4.4x
Quick ratio 7.1x8.8x5.4x3.1x4.2x
Total assets $330M$382M$333M$392M$480M
Total liabilities $45.4M$118M$163M$228M$210M
Shareholders' equity $284M$264M$170M$21.7M$139M
Net debt (− = net cash) ——−$170M−$211M−$281M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Cash from operations is positive ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Return on assets rose — ✓ ✕ ✕ ✕ ✓ ✕ ✕ ✕ ✓
Cash from operations exceeds net income ✓ ✓ ✓ ✓ ✓ ✕ ✓ ✓ ✓ ✓
Debt fell relative to assets — — — — — — — — ✓ ✓
Current ratio rose — ✓ ✕ ✕ ✕ ✕ ✓ ✕ ✕ ✓
Share count didn't rise — ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Gross margin rose — — — — — — ✓ ✕ ✓ ✓
Revenue rose relative to assets — ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✓
F-score — / 33 / 71 / 71 / 71 / 72 / 74 / 82 / 84 / 96 / 9
Accruals ratio −21.5%−5.2%−5.8%−6.3%−4.8%29.6%−2.2%−13.6%−40.5%−18.5%
Altman Z'' −37.7224.3020.3710.021.343.15−1.46−6.41−9.72−6.24

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $0.0M $0.0M $0.0M $0.0M $0.0M $3.2M $23.6M $77.4M $130M $190M
Gross profit — — — — — $2.6M $21.5M $68.1M $117M $170M
Research and development $19.6M $22.9M $50.3M $109M $90.5M $104M $109M $135M $238M $167M
Operating income −$25.9M −$32.4M −$78.4M −$146M −$137M −$170M −$179M −$184M −$266M −$192M
Interest expense — — — — — — $5.2M $13.9M $20.6M $20.6M
Pretax income — — — — — −$69.6M −$181M −$184M −$260M −$196M
Income tax — — — — — — — $0.6M $0.3M $0.5M
Net income −$25.9M −$33.7M −$74.1M −$141M −$134M −$69.6M −$181M −$185M −$261M −$197M
Net income to common −$29.1M −$37.6M −$74.1M −$141M −$134M — −$181M −$185M −$265M −$202M
Diluted EPS −$2.85 −$2.83 −$2.39 −$3.86 −$3.04 −$1.40 −$3.47 −$3.20 −$4.34 −$3.11
Diluted shares 0.01B 0.01B 0.03B 0.04B 0.04B 0.05B 0.05B 0.06B 0.06B 0.06B
Cash flow
Cash from operations −$23.2M −$29.5M −$62.1M −$123M −$122M −$146M −$173M −$136M −$114M −$116M
Capital expenditure $1.1M $0.1M $0.7M $3.4M $0.2M $0.4M $0.3M $0.0M $0.0M $1.0M
Free cash flow −$24.3M −$29.6M −$62.8M −$126M −$122M −$146M −$174M −$136M −$114M −$117M
Depreciation and amortization $0.1M $0.2M $0.4M $0.8M $0.7M $0.8M $0.9M $0.9M $0.7M $0.5M
Stock-based compensation $1.2M $2.3M $6.4M $11.9M $17.5M $20.8M $19.8M $32.6M $39.7M $66.8M
Balance sheet
Cash and short-term investments $6.5M $34.2M $49.5M $292M $173M $295M $333M $276M $321M $389M
Total debt — — — — — — — $106M $110M $108M
Current assets $11.2M $151M $259M $302M $182M $308M $354M $308M $374M $467M
Current liabilities $4.7M $6.7M $13.6M $24.4M $18.0M $43.4M $39.8M $55.2M $116M $106M
Inventory — — — — — $0.1M $2.9M $8.6M $18.7M $25.8M
Property and equipment, net $0.9M $0.8M $1.1M $3.7M $3.2M $2.8M $2.2M $1.3M $0.6M $1.1M
Intangible assets — — — — — $4.7M $7.9M $7.0M $6.2M $5.3M
Total assets $12.3M $152M $260M $309M $187M $330M $382M $333M $392M $480M
Total liabilities $5.0M $6.9M $14.0M $27.5M $20.5M $45.4M $118M $163M $228M $210M
Preferred stock — — — — — — — — — $0.0M
Shareholders' equity −$32.7M $145M $246M $281M $167M $284M $264M $170M $21.7M $139M
Margins
Gross margin — — — — — 81.0% 91.0% 88.0% 89.7% 89.7%
Operating margin — — — — — −5,391.9% −757.9% −238.1% −204.0% −101.2%
EBITDA margin — — — — — −5,366.0% −754.1% −236.9% −203.5% −100.9%
Net margin — — — — — −2,207.1% −766.2% −238.5% −200.3% −103.6%
FCF margin — — — — — −4,642.9% −734.9% −175.9% −87.5% −61.5%
Returns
Return on capital — — — — — — — −260,075.1% — —
Return on capital employed −340.5% −22.4% −31.8% −51.4% −80.8% −59.4% −52.3% −66.4% −95.9% −51.3%
Return on equity — −60.1% −37.9% −53.4% −59.9% −30.9% −66.1% −85.1% −272.2% −244.5%
Return on assets −209.7% −41.1% −36.0% −49.5% −54.1% −27.0% −50.9% −51.6% −71.9% −45.1%
Return on tangible equity — −26.0% −30.1% −50.1% −80.5% −24.9% −70.6% −113.5% −1,700.9% −151.0%
Growth
Revenue growth — — — — — — 649.5% 227.6% 68.1% 45.8%
Share count change — 30.1% 133.7% 17.5% 21.2% 12.4% 5.1% 10.7% 5.8% 6.5%
Financial health
Debt / equity — — — — — — — 0.6x 5.1x 0.8x
Interest coverage — — — — — — −34.4x −13.3x −12.9x −9.3x
Current ratio 2.4x 22.4x 19.0x 12.4x 10.1x 7.1x 8.9x 5.6x 3.2x 4.4x
Quick ratio 2.4x 22.4x 19.0x 12.4x 10.1x 7.1x 8.8x 5.4x 3.1x 4.2x
Capital allocation
Capex / revenue — — — — — 13.8% 1.2% 0.1% 0.0% 0.5%
Stock comp / revenue — — — — — 659.6% 83.9% 42.0% 30.5% 35.2%
Quality scores
Piotroski F-score — 3.0 1.0 1.0 1.0 2.0 4.0 2.0 4.0 6.0
Altman Z'' −37.7 24.3 20.4 10.0 1.3 3.1 −1.5 −6.4 −9.7 −6.2
Accruals ratio −21.5% −5.2% −5.8% −6.3% −4.8% 29.6% −2.2% −13.6% −40.5% −18.5%

Source: SEC EDGAR XBRL filings (CIK 0001649904). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open